Cite
HARVARD Citation
Mease, P. et al. (n.d.). SAT0470 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year efficacy and safety results from phase 3 future 1 trial. Annals of the rheumatic diseases. pp. 952-953. [Online].